Department of Psychiatry and Psychotherapy, University of Erlangen-Nuremberg, Erlangen, Germany.
Exp Neurol. 2010 Jun;223(2):366-70. doi: 10.1016/j.expneurol.2009.07.024. Epub 2009 Aug 5.
We measured concentrations of Abeta peptides 1-42 and 1-40, and their ratio in plasma of patients carefully categorized clinically and neurochemically as having AD or other dementias with a newly commercially available multiplexing assay, characterized by reasonable laboratory performance (intra-assay imprecision in the range of 1.3-3.8% for Abeta1-42, and 1.8-4.1% for Abeta1-40, inter-assay imprecision for Abeta1-42, Abeta1-40, and Abeta1-42/Abeta1-40 concentration ratio in the range of 2.3-11.5%, 2.2-10.4% and 4.2-9.7%, respectively). Patients with AD or mild cognitive impairment of AD type (MCI-AD) whose clinical diagnosis was supported with CSF biomarkers (n=193) had significantly lower Abeta1-42 plasma concentrations (p<0.007), and Abeta1-42/1-40 ratios (p<0.003) compared to patients with other dementias and MCI of other types (n=64). No significant differences between persons with MCI of AD type and patients with early AD were observed, or between MCI of other types versus patients with early dementia of other types. Our findings reconfirm the hypothesis that alterations of biomarker concentrations occur early in a preclinical AD stage and that these alterations are also reflected in plasma.
我们使用一种新的商业上可获得的多重分析测定法，对经过临床和神经化学精心分类的 AD 或其他类型痴呆患者的血浆 Abeta 肽 1-42 和 1-40 及其比值进行了测量，该方法具有合理的实验室性能（Abeta1-42 的测定内不精密度在 1.3-3.8%范围内，Abeta1-40 的测定内不精密度在 1.8-4.1%范围内，Abeta1-42、Abeta1-40 和 Abeta1-42/Abeta1-40 浓度比的测定间不精密度分别在 2.3-11.5%、2.2-10.4%和 4.2-9.7%范围内）。有脑脊液生物标志物支持临床诊断的 AD 或 AD 型轻度认知障碍（MCI-AD）患者（n=193）的 Abeta1-42 血浆浓度显著降低（p<0.007），Abeta1-42/1-40 比值也显著降低（p<0.003），与其他类型痴呆和其他类型 MCI 患者（n=64）相比。未观察到 AD 型 MCI 患者与早期 AD 患者之间存在显著差异，或其他类型 MCI 患者与其他类型早期痴呆患者之间存在显著差异。我们的发现再次证实了这样一种假说，即生物标志物浓度的改变发生在 AD 的临床前阶段较早时期，并且这些改变也反映在血浆中。
